HC Wainwright Reaffirms “Neutral” Rating for Inovio Pharmaceuticals (NASDAQ:INO)

HC Wainwright reiterated their neutral rating on shares of Inovio Pharmaceuticals (NASDAQ:INO – Free Report) in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a $15.00 price target on the biopharmaceutical company’s stock. Several other research firms have also recently commented on INO. Stephens began coverage on shares of Inovio […]

Leave a Reply

Your email address will not be published.

Previous post Fastenal (NASDAQ:FAST) Stock Rating Reaffirmed by Stephens
Next post Piper Sandler Cuts Atlas Energy Solutions (NYSE:AESI) Price Target to $27.00